DOCSLIB.ORG

Human Health and Environmental Sustainability in Pathogenic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Human Health and Environmental Sustainability in Pathogenic HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY IN PATHOGENIC LANDSCAPES: FEEDBACKS AND SOLUTIONS A DISSERTATION SUBMITTED TO THE DEPARTMENT OF BIOLOGY AND THE COMMITTEE ON GRADUATE STUDIES OF STANFORD UNIVERSITY IN PARTIAL FUFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY ISABEL JEAN JONES AUGUST 2020 © 2020 by Isabel Jean Jones. All Rights Reserved. Re-distributed by Stanford University under license with the author. This work is licensed under a Creative Commons Attribution- Noncommercial 3.0 United States License. http://creativecommons.org/licenses/by-nc/3.0/us/ This dissertation is online at: http://purl.stanford.edu/fv856hm0269 ii I certify that I have read this dissertation and that, in my opinion, it is fully adequate in scope and quality as a dissertation for the degree of Doctor of Philosophy. Giulio De Leo, Primary Adviser I certify that I have read this dissertation and that, in my opinion, it is fully adequate in scope and quality as a dissertation for the degree of Doctor of Philosophy. Erin Mordecai I certify that I have read this dissertation and that, in my opinion, it is fully adequate in scope and quality as a dissertation for the degree of Doctor of Philosophy. Stephen Palumbi Approved for the Stanford University Committee on Graduate Studies. Stacey F. Bent, Vice Provost for Graduate Education This signature page was generated electronically upon submission of this dissertation in electronic format. An original signed hard copy of the signature page is on file in University Archives. iii Abstract Feedbacks between human health, well-being, and environmental sustainability are increasingly well recognized, but evidence on ActionAble solutions to leverAge tHese feedbAcks And improve their outcomes is limited. And yet, the recently adopted United NAtions SustainAble Development GoAls compel decision makers to achieve health for all people while reducing poverty and conserving nature. This dissertation attempts to fill this urgent research gap and empirically assess feedbacks between human health and the environment from two perspectives: (i) environmentAl drivers of diseAse in cHAnging lAndscApes, And (ii) consequences of Human HeAltH and well-being on environmental change and conservation outcomes. But first, using synthesis science, we describe the environmental components of the world’s most burdensome human parasitic and infectious diseases, then assess a specific type of ecosystem service – natural enemies of human infections – as a sustainable tool to reduce some communicable diseases. Then, we Assess feedbAcks between HumAn HeAltH And environmental sustainability through two datA-ricH cAse studies. First, in the SenegAl River BAsin, a region hyperendemic for scHistosomiasis diseAse, we assess ecologicAl associations and spAtial scAles of humAn diseAse risk. In this region, scHistosomiasis diseAse, which is transmitted to humans by freshwater snail hosts, can be caused by two species of schistosome parasites (and their two unique snail hosts). The World HeAltH OrgAnizAtion currently recommends tHAt snAil control be implemented in endemic areas to curb transmission. However, snail control methods rarely take into consideration the unique transmission dynAmics of co-endemic species, which could interfere with control outcomes for one or both species. So here we ask a critical question: whAt is tHe spatial scale and ecological correlates of schistosomiasis risk, considering two distinct schistosome species in a co- endemic landscape? We find specific, yet divergent, ecologicAl correlAtes And spAtiAl scAles of risk for eAcH species. UltimAtely, these findings can be used to design ecological levers for health (like snAil control) thAt best reflect the unique transmission ecology the targeted species. Second, in rural Borneo, we assess the impAct of a 10-year, on-the-ground intervention aiming to improve Human health care access in order to curb illegal logging in protected forests, and ask: Is healthcare an effective lever for conservation? Using earth observation, household surveys, and clinic data records, we find that the intervention provided health care access for more thAn 28,000 patients and averted >27km2 forest loss (~70% reduction compAred to controls), thus improving human health and well-being, and simultaneously preserving globally important forest carbon. In conclusion, this dissertation shows thAt, by recognizing and embracing complex mecHAnisms driving healtH-environment feedbacks, we can identify effective ecological levers for human health, and health levers for conservation. iv Acknowledgements Many people Helped tHis dissertAtion come together, but there are two people thAt facilitated and supported each and every part: Giulio De Leo and Susanne Sokolow. To my generous advisor and powerhouse mentor, many tHAnks for your continued personAl And AcAdemic support, and for always putting my well-being ahead of my work. I also hAd an excellent dissertation committee thAt cHAllenged and supported me, so thAnk you to Erin MordecAi and Steve PAlumbi. Andy, many thAnks to Steve Luby and Rodolfo Dirzo for joining my oral defense committee. Outside of Stanford, no smAll amount of guidAnce, patient teaching, and friendship came from Chelsea Wood, SkylAr Hopkins, And Andy MAcDonAld. ThAnks Also to tHe NCEAS SNAPP working group, “Ecological Levers for Health”, for welcoming me into an incredible community of reseArcHers thAt I was first intimidAted by but can now call friends and colleagues. The most rewArding aspect of my reseArcH experience wAs the opportunity to work with reseArcHers, conservation practitioners, health care providers, activists, and community members working on- the-ground, around-the-clock to make real positive change to the daily lives of people, to protect and restore the natural world, and to enact climate change mitigation. To that end, thank you to the UpstreAm Alliance teAm in Senegal for supported me during five amAzing field trips to the Senegal River Basin, to HeAltH In Harmony in PortlAnd and Alam Sehat Lestari in Borneo for endless inspiration, to MArtinA LAidemitt and Dr. SAm Loker for welcoming to join in and leArn from their incredible long-term field reseArcH at Lake Victoria in Kenya, and to PIVOT in MadAgAscAr for generously Hosting me for a truly unique reseArcH experience in IfanAdianA. AndreA Lund was tHe best dissertAtion partner and friend to have along the way – thAnk you for reminding me thAt “a good dissertation is a done dissertation”. My friends – the bAsketbAll champions in the De Leo Lab, Tim White, SerenA Lomonico, A2 Andy ChAmberlAin & Alex Smith, and Shirel Kahane-Rapport – made life in Monterey fun And interesting, And convinced me to stay put in this mAgical place as long as possible, wHicH is exActly wHAt I’ll do. Luke NetscH has been a stellar partner and has made Monterey and its beaches and mountains a lovely home for us. My fAmily – Laurel, Robert, AmAndA, HannAH, Chris, Kyle, JeAn, Emer, DiAne – remind me every day what’s most important. RutH, you Are tHe best. v vi Table of Contents Abstract ............................................................................................................................. iv Acknowledgements .................................................................................................................... v Introduction ....................................................................................................................... 1 Chapter 1 : Biodiversity and environmentAl persistence of the world’s most burdensome infectious and parasitic diseAses ........................................................................................ 10 Chapter 2 : Enemy of my enemy: NAtural enemies for sustAinable control of humAn infections ........................................................................................................................... 28 Chapter 3 : Divergent ecologicAl drivers and spatiAl scAles of risk for S. haemAtobium And S. mAnsoni in a co-endemic lAndscApe ....................................................................... 63 Chapter 4 : Improving rural heAlth cAre reduces illegal logging and conserves cArbon in A tropicAl forest .................................................................................................................. 98 Conclusion ...................................................................................................................... 156 vii List of Illustrations Figure 1.1. AssociAtions between duration of infectious stAges in the environment, transmission strategies, control strategies, host ranges, and global cAses of diseAse ....... 23 Figure 2.1. NAtural enemies of humAn infectious diseAses in the environment .............. 57 Figure 2.2. Reports of mosquito vector resistAnce to insecticides over time (A) and natural enemies of mosquitoes (B) .................................................................................. 58 Figure 3.1. Study locAtion (A); examples of overheAd drone imAgery and high-resolution imAge clAssificAtion into dominant aquatic habitAt types (B–C) ..................................... 88 Figure 3.2. EstimAted mArginal meAns for Bulinus spp. (A–B) and Biomphalaria pfeifferi (C–D) snails in three dominant aquatic HAbitAt types ...................................................... 89 Figure 3.3. VisualizAtion of experimentAl design to explore scAle of diseAse transmission risk (A); correlAtion between non-emergent vegetAtion and S. haematobium And S. mansoni infection
Load more

Recommended publications
  • The Search for a Schistosomiasis Vaccine: Australia’S Contribution
    Review The Search for a Schistosomiasis Vaccine: Australia’s Contribution Donald P. McManus Molecular Parasitology Laboratory, Infectious Diseases Division, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia; [email protected]; Tel.: +61-418-744-006 Abstract: Schistosomiasis, a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma, results in considerable human morbidity in sub-Saharan Africa, in particular, but also parts of the Middle East, South America, and Southeast Asia. The anti-schistosome drug praziquantel is efficacious and safe against the adult parasites of all Schistosoma species infecting humans; however, it does not prevent reinfection and the development of drug resistance is a constant concern. The need to develop an effective vaccine is of great importance if the health of many in the developing world is to be improved. Indeed, vaccination, in combination with other public health measures, can provide an invaluable tool to achieve lasting control, leading to schistosomiasis elimination. Australia has played a leading role in schistosomiasis vaccine research over many years and this review presents an overview of some of the significant contributions made by Australian scientists in this important area. Keywords: Schistosoma; schistosomiasis; vaccine; vaccination; Australia; Australian researchers 1. Introduction Citation: McManus, D.P. The Search for a Schistosomiasis Vaccine: The neglected tropical parasitic disease of schistosomiasis, caused by blood flukes of Australia’s Contribution. Vaccines the genus Schistosoma, has long been a scourge of humankind. It results in considerable 2021, 9, 872. https://doi.org/ morbidity, even leading to death, in sub-Saharan Africa, parts of South America, the Middle 10.3390/vaccines9080872 East and Southeast Asia.
    [Show full text]
  • Library of Congress Classification
    R MEDICINE (GENERAL) R Medicine (General) Periodicals. Societies. Serials 5 International periodicals and serials 10 Medical societies Including aims, scope, utility, etc. International societies 10.5.A3 General works 10.5.A5-Z Individual societies America English United States. Canada 11 Periodicals. Serials 15 Societies British West Indies. Belize. Guyana 18 Periodicals. Serials 20 Societies Spanish and Portuguese Latin America 21 Periodicals. Serials 25 Societies 27.A-Z Other, A-Z 27.F7 French Europe English 31 Periodicals. Serials 35 Societies Dutch 37 Periodicals. Serials 39 Societies French 41 Periodicals. Serials 45 Societies German 51 Periodicals. Serials 55 Societies Italian 61 Periodicals. Serials 65 Societies Spanish and Portuguese 71 Periodicals. Serials 75 Societies Scandinavian 81 Periodicals. Serials 85 Societies Slavic 91 Periodicals. Serials 95 Societies 96.A-Z Other European languages, A-Z 96.H8 Hungarian Asia 97 English 97.5.A-Z Other European languages, A-Z 97.7.A-Z Other languages, A-Z Africa 98 English 98.5.A-Z Other European languages, A-Z 98.7.A-Z Other languages, A-Z 1 R MEDICINE (GENERAL) R Periodicals. Societies. Serials -- Continued Australasia and Pacific islands 99 English 99.5.A-Z Other European languages, A-Z 99.7.A-Z Other languages, A-Z Indexes see Z6658+ (101) Yearbooks see R5+ 104 Calendars. Almanacs Cf. AY81.M4 American popular medical almanacs 106 Congresses 108 Medical laboratories, institutes, etc. Class here papers and proceedings For works about these organizations see R860+ Collected works (nonserial) Cf. R126+ Ancient Greek and Latin works 111 Several authors 114 Individual authors Communication in medicine Cf.
    [Show full text]
  • Trivia Questions
    TRIVIA QUESTIONS Submitted by: ANS Savannah River - A. Bryson, D. Hanson, B. Lenz, M. Mewborn 1. What was the code name used for the first U.S. test of a dry fuel hydrogen bomb? Castle Bravo 2. What was the name of world’s first artificial nuclear reactor to achieve criticality? Chicago Pile-1 (CP-1), I also seem to recall seeing/hearing them referred to as “number one,” “number two,” etc. 3. How much time elapsed between the first known sustained nuclear chain reaction at the University of Chicago and the _____ Option 1: {first use of this new technology as a weapon} or Option 2: {dropping of the atomic bomb in Hiroshima} A3) First chain reaction = December 2nd 1942, First bomb-drop = August 6th 1945 4. Some sort of question drawing info from the below tables. For example, “what were the names of the other aircraft that accompanied the Enola Gay (one point for each correct aircraft name)?” Another example, “What was the common word in the call sign of the pilots who flew the Japanese bombing missions?” A4) Screenshots of tables from the Wikipedia page “Atomic bombings of Hiroshima and Nagasaki” Savannah River Trivia / Page 1 of 18 5. True or False: Richard Feynman’s name is on the patent for a nuclear powered airplane? (True) 6. What is the Insectary of Bobo-Dioulasso doing to reduce the spread of sleeping sickness and wasting diseases that affect cattle using a nuclear technique? (Sterilizing tsetse flies; IAEA.org) 7. What was the name of the organization that studied that radiological effects on people after the atomic bombings? Atomic Bomb Casualty Commission 8.
    [Show full text]
  • 2015 Review Conference of the Parties to the Treaty
    NPT/CONF.2015/38 2015 Review Conference of the Parties Distr.: General to the Treaty on the Non-Proliferation 1 May 2015 of Nuclear Weapons Original: English New York, 27 April-22 May 2015 Actions 5, 20 and 21 of the action plan of the 2010 Review Conference of the Parties to the Treaty on the Non-Proliferation of Nuclear Weapons* Report submitted by the United States of America As provided in the 2010 Nuclear Non-Proliferation Treaty (NPT) Review Conference Action Plan, the Governments of the five NPT nuclear-weapon states, or “P5,” are working to implement Action 5 to “(f)urther enhance transparency and increase mutual confidence” and to make national reports on our Action 5 and other undertakings to the 2014 NPT Preparatory Committee under a common framework, consistent with Actions 20 and 21. Action 21 states “As a confidence-building measure, all the nuclear-weapon States are encouraged to agree as soon as possible on a standard reporting form and to determine appropriate reporting intervals for the purpose of voluntarily providing standard information without prejudice to national security.” The framework we use for our national reports includes common categories of topics under which relevant information is reported, and it addresses all three pillars of the NPT: disarmament, non-proliferation, and peaceful uses of nuclear energy. We encourage all States Parties, consistent with Action 20, to make similar reports. Having provided our initial report to the 2014 NPT Preparatory Committee, here we provide an update including actions in the past year for the 2015 NPT Review Conference.
    [Show full text]
  • Human African Trypanosomiasis: the Current Situation in Endemic Regions and the Risks for Cambridge.Org/Par Non-Endemic Regions from Imported Cases
    Parasitology Human African trypanosomiasis: the current situation in endemic regions and the risks for cambridge.org/par non-endemic regions from imported cases 1,2 1 3 2 Review Jiang-Mei Gao , Zheng-Yu Qian , Geoff Hide , De-Hua Lai , Zhao-Rong Lun1,2,3 and Zhong-Dao Wu1 Cite this article: Gao J-M, Qian Z-Y, Hide G, Lai D-H, Lun Z-R, Wu Z-D (2020). Human African 1Key Laboratory of Tropical Disease Control of the Ministry of Education, Zhongshan School of Medicine, Sun trypanosomiasis: the current situation in Yat-Sen University, Guangzhou 510275, China; 2Center for Parasitic Organisms, State Key Laboratory of Biocontrol, endemic regions and the risks for non- 3 endemic regions from imported cases. School of Life Sciences, Sun Yat-Sen University, Guangzhou 510275, China and Biomedical Research Centre and Parasitology 147,922–931. https://doi.org/ Ecosystems and Environment Research Centre, School of Science, Engineering and Environment, University of 10.1017/S0031182020000645 Salford, Salford, M5 4WT, UK Received: 20 March 2020 Abstract Revised: 12 April 2020 Accepted: 13 April 2020 Human African trypanosomiasis (HAT) is caused by Trypanosoma brucei gambiense and First published online: 27 April 2020 Trypanosoma brucei rhodesiense and caused devastating epidemics during the 20th century. Key words: Due to effective control programs implemented in the last two decades, the number of Human African trypanosomiasis; non-endemic reported cases has fallen to a historically low level. Although fewer than 977 cases were disease countries; sub-Saharan Africa; reported in 2018 in endemic countries, HAT is still a public health problem in endemic T.
    [Show full text]
  • Recent Progress in the Development of Liver Fluke and Blood Fluke Vaccines
    Review Recent Progress in the Development of Liver Fluke and Blood Fluke Vaccines Donald P. McManus Molecular Parasitology Laboratory, Infectious Diseases Program, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia; [email protected]; Tel.: +61-(41)-8744006 Received: 24 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: Liver flukes (Fasciola spp., Opisthorchis spp., Clonorchis sinensis) and blood flukes (Schistosoma spp.) are parasitic helminths causing neglected tropical diseases that result in substantial morbidity afflicting millions globally. Affecting the world’s poorest people, fasciolosis, opisthorchiasis, clonorchiasis and schistosomiasis cause severe disability; hinder growth, productivity and cognitive development; and can end in death. Children are often disproportionately affected. F. hepatica and F. gigantica are also the most important trematode flukes parasitising ruminants and cause substantial economic losses annually. Mass drug administration (MDA) programs for the control of these liver and blood fluke infections are in place in a number of countries but treatment coverage is often low, re-infection rates are high and drug compliance and effectiveness can vary. Furthermore, the spectre of drug resistance is ever-present, so MDA is not effective or sustainable long term. Vaccination would provide an invaluable tool to achieve lasting control leading to elimination. This review summarises the status currently of vaccine development, identifies some of the major scientific targets for progression and briefly discusses future innovations that may provide effective protective immunity against these helminth parasites and the diseases they cause. Keywords: Fasciola; Opisthorchis; Clonorchis; Schistosoma; fasciolosis; opisthorchiasis; clonorchiasis; schistosomiasis; vaccine; vaccination 1. Introduction This article provides an overview of recent progress in the development of vaccines against digenetic trematodes which parasitise the liver (Fasciola hepatica, F.
    [Show full text]
  • The Tripartite Council of Khanbogd Soum, Umnugovi Aimag Cover Letter to Final Report of MDT and IEP
    The Tripartite Council of Khanbogd soum, Umnugovi aimag Cover Letter to Final Report of MDT and IEP Khanbogd soum Umnugovi aimag Mongolia January 12, 2017 The reports of the socio-economic study of Khanbogd soum herder households and Phase 2 study of cumulative impact of Undai River diversion conducted by the independent experts employed by the Tripartite Council (TPC)1 of Khanbogd soum, Umnugovi aimag, are hereby disclosed to the public. This study was carried out to facilitate the resolution of complaints lodged by Khanbogd soum herders with the Office of the Compliance Advisor Ombudsman (CAO) of the World Bank Group. The purpose of study was to map independently and objectively the changes over the last decade in livelihood and socio-economic conditions of Khanbogd soum herder households, based on information from diverse sources, and subsequently to determine which changes were caused by or attributable to Oyu Tolgoi (OT) company operations. In addition, the study aimed to assess the adequacy of the OT’s compensation programs, cumulative impacts on regional water and pasture resources due to Undai, Khaliv and Dugat River Diversions, and impacts from OT tailings’ storage facility. Multi-Disciplinary Team (MDT) and Independent Experts’ Panel (IEP) carried out the studies in 2016 and submitted the final report to the TPC of Khanbogd Soum in January, 2017. Conclusions provided in the report by MDT and IEP are not the TPC’s position; and the report presents solely independent conclusions and assessments of the independent experts. We notify any interested entities herein that some conclusions of the report are not fully accepted by the parties of TPC.
    [Show full text]
  • 2012 NIAID Jordan Report
    THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases Images on cover, from the top: Courtesy of the US Centers for Disease Control and Prevention; istock.com; Courtesy of the National Library of Medicine; Courtesy of MedImmune THE JORDAN REPORT ACCELERATED DEVELOPMENT OF VACCINES 2012 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases NIH Publication No. 11-7778 January 2012 www.niaid.nih.gov ADDITIONAL RESOURCES National Institute of Allergy and Infectious Diseases, www.niaid.nih.gov Vaccines.gov: your best shot at good health, www.vaccines.gov Centers for Disease Control and Prevention: Immunization Schedules, www.cdc.gov/vaccines/recs/schedules/ Table of Contents INTRODUCTION VACCINE UPDATES Foreword by Anthony S. Fauci, M.D. ......................................... 3 Dengue M. Cristina Cassetti, Ph.D. .......................................................... 95 Tribute by Carole A. Heilman, Ph.D. ......................................... 5 HIGHLIGHT BOX Vaccine Against Chikungunya Virus in Development EXPERT ARTICLES Gary J. Nabel, M.D., Ph.D. and Ken Pekoc ......................... 97 Vaccinomics and Personalized Vaccinology Severe Acute Respiratory Syndrome Gregory A. Poland, M.D., Inna G. Ovsyannikova, Ph.D. and Frederick J. Cassels, Ph.D. ............................................................ 98 Robert M. Jacobson, M.D. .............................................................11 HIGHLIGHT BOX Sex Differences in Immune Responses to Vaccines Vaccine Delivery Technologies Col. Renata J. M. Engler, M.D. and Mary M. Klote, M.D. ....... 19 Martin H. Crumrine, Ph.D. ................................................. 105 Immunization and Pregnancy West Nile Virus Flor M. Munoz, M.D. .................................................................. 27 Patricia M. Repik, Ph.D.
    [Show full text]
  • Developing Vaccines to Combat Hookworm Infection and Intestinal Schistosomiasis
    REVIEWS Developing vaccines to combat hookworm infection and intestinal schistosomiasis Peter J. Hotez*, Jeffrey M. Bethony*‡, David J. Diemert*‡, Mark Pearson§ and Alex Loukas§ Abstract | Hookworm infection and schistosomiasis rank among the most important health problems in developing countries. Both cause anaemia and malnutrition, and schistosomiasis also results in substantial intestinal, liver and genitourinary pathology. In sub-Saharan Africa and Brazil, co-infections with the hookworm, Necator americanus, and the intestinal schistosome, Schistosoma mansoni, are common. The development of vaccines for these infections could substantially reduce the global disability associated with these helminthiases. New genomic, proteomic, immunological and X-ray crystallographic data have led to the discovery of several promising candidate vaccine antigens. Here, we describe recent progress in this field and the rationale for vaccine development. In terms of their global health impact on children and that combat hookworm and schistosomiasis, with an pregnant women, as well as on adults engaged in subsist- emphasis on disease caused by Necator americanus, the ence farming, human hookworm infection (known as major hookworm of humans, and Schistosoma mansoni, ‘hookworm’) and schistosomiasis are two of the most the primary cause of intestinal schistosomiasis. common and important human infections1,2. Together, their disease burdens exceed those of all other neglected Global distribution and pathobiology tropical diseases3–6. They also trap the world’s poorest Hookworms are roundworm parasites that belong to people in poverty because of their deleterious effects the phylum Nematoda. They share phylogenetic simi- on child development and economic productivity7–9. larities with the free-living nematode Caenorhabditis Until recently, the importance of these conditions as elegans and with the parasitic nematodes Nippostrongylus global health and economic problems had been under- brasiliensis and Heligmosomoides polygyrus, which are appreciated.
    [Show full text]
  • Schistosomiasis Vaccine Development: Update on Human Clinical Trials Adebayo J
    Molehin Journal of Biomedical Science (2020) 27:28 https://doi.org/10.1186/s12929-020-0621-y REVIEW Open Access Schistosomiasis vaccine development: update on human clinical trials Adebayo J. Molehin1,2 Abstract Schistosomiasis causes significant levels of morbidity and mortality in many geographical regions of the world. The disease is caused by infections with parasitic blood flukes known as schistosomes. The control of schistosomiasis over the last several decades has been centered on the mass drug administration (MDA) of praziquantel (PZQ), which is the only drug currently available for treatment. Despite the concerted efforts of MDA programs, the prevalence and transmission of schistosomiasis has remained largely unchecked due to the fact that PZQ is ineffective against juvenile schistosomes, does not prevent re-infection and the emergence of PZQ-resistant parasites. In addition, other measures such as the water, sanitation and hygiene programs and snail intermediate hosts control have had little to no impact. These drawbacks indicate that the current control strategies are severely inadequate at interrupting transmission and therefore, implementation of other control strategies are required. Ideally, an efficient vaccine is what is needed for long term protection thereby eliminating the current efforts of repeated mass drug administration. However, the general consensus in the field is that the integration of a viable vaccine with MDA and other control measures offer the best chance of achieving the goal of schistosomiasis elimination.
    [Show full text]
  • Schistosomiasis Vaccines: Where Do We Stand? Biniam Mathewos Tebeje1,2,3*, Marina Harvie1, Hong You1, Alex Loukas4 and Donald P
    Tebeje et al. Parasites & Vectors (2016) 9:528 DOI 10.1186/s13071-016-1799-4 REVIEW Open Access Schistosomiasis vaccines: where do we stand? Biniam Mathewos Tebeje1,2,3*, Marina Harvie1, Hong You1, Alex Loukas4 and Donald P. McManus1* Abstract Schistosomiasis, caused mainly by S. mansoni, S. haematobium and S. japonicum, continues to be a serious tropical disease and public health problem resulting in an unacceptably high level of morbidity in countries where it is endemic. Praziquantel, the only drug currently available for treatment, is unable to kill developing schistosomes, it does not prevent re-infection and its continued extensive use may result in the future emergence of drug-resistant parasites. This scenario provides impetus for the development and deployment of anti-schistosome vaccines to be used as part of an integrated approach for the prevention, control and eventual elimination of schistosomiasis. This review considers the present status of candidate vaccines for schistosomiasis, and provides some insight on future vaccine discovery and design. Keywords: Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, Immune response, Schistosomiasis, Vaccine, Immune protection, Antigen discovery Background is supplied regularly in timely fashion to all parts of an The World Health Organization (WHO) considers endemic area. schistosomiasis to be second only to malaria as the most Originally used as a major preventative measure [6], devastating parasitic disease in terms of socioeconomic snail control, through the use of molluscicides (e.g. importance and public health impact [1]. Human infec- niclosamide), is now not the recommended method in tion is due to three main species, namely Schistosoma isolation for the prevention of schistosomiasis [5].
    [Show full text]
  • CURRICULUM VITAE Ernesto T Marques, M.D; Ph.D
    CURRICULUM VITAE Ernesto T Marques, M.D; Ph.D. University of Pittsburgh Business 2131 Public Health, 130 Business Phone: (412) 624-1529 Address: DeSoto Street, Pittsburgh, (443) 509 3022 PA 15261 E-mail: [email protected] Business Fax: (XXXXXX) Email Address: [email protected] Home Address: 106 North Woodland Rd Home Phone: (412) 361-0275 Pittsburgh, PA 15232 Birthplace: Recife, Brazil Citizenship: American, Brazilian and Portuguese-EU EDUCATION and TRAINING Undergraduate 1987 - 1993 Universidade Federal de Pernambuco - M.D. UFPE Medicine Recife, Brazil Jose Luiz de Lima Filho Summa cum laude - Top academic performance in the 1993 class Graduate 1994 - 1999 The Johns Hopkins University Ph.D. School of Medicine Pharmacology and Molecular Baltimore, Maryland Sciences Mette Strand, Gerald Hart and Ronald Schnaar Postgraduate 1993 - 1994 Universidade Federal de Pernambuco - Anesthesiology UFPE Tereza Maciel Recife, Recife 10/19/2020 Ernesto T Marques, M.D/Ph.D. Page 1 of 50 APPOINTMENTS and POSITIONS Academic 1999 - 2005 School of Medicine Research Faculty The Johns Hopkins University Pharmacology and Molecular Baltimore, Maryland Sciences 2003 – Present FIOCRUZ-Pernambuco Senior Public Health Scientist Fundação Oswaldo Cruz - FIOCRUZ Department of Virology and Recife, Brazil Experimental Therapeutics 2005 - 2009 School of Medicine Assistant Professor The Johns Hopkins University Medicine Baltimore, Maryland 2009 - Present Graduate School of Public Health Associate Professor University of Pittsburgh Infectious Diseases and Pittsburgh Microbiology
    [Show full text]